From human breakthroughs to canine cures.
Unleash Therapeutics is turning human oncology innovations into life-saving cancer treatments for dogs.
Cancer shouldn’t be a death sentence for dogs.
Each year, more than 6 million dogs in the U.S. are diagnosed with cancer—four times the number of human cases. Yet, despite decades of progress in human oncology, there are only three FDA-approved drugs for canine cancer.
With Unleash Therapeutics, we want to change that. Our mission is to transform canine cancer care by developing effective, accessible therapeutics that extend and improve the lives of dogs with cancer.
A diversified portfolio of canine oncology assets.
Unleash Therapeutics is developing a portfolio of oncology therapeutics for dogs, targeting multiple high-prevalence canine cancers and leveraging the efficiency of comparative oncology data.
FEATURED ASSET
K9-ACV + CD200AR-L
This pioneering combination therapy is being evaluated for the treatment of canine osteosarcoma. The ongoing clinical trial, in partnership with Ardent Animal Health, is evaluating the safety and efficacy of K9-ACV, an autologous killed tumor cell vaccine, combined with CD200AR-L, a novel checkpoint inhibitor, compared to standard-of-care chemotherapy for the treatment of canine appendicular osteosarcoma (OSA).